B2M and Miyoshi myopathy: In comparison to previous MM staging systems which exclusively relied on biomarkers such as serum albumin, beta-2 microglobulin, and serum lactate dehydrogenase, this system also takes into consideration high-risk cytogenetic abnormalities such as deletion 17p, translocations of chromosome 14, and gains of 1q [6].